MediciNova Presenting New Data from the P-II Study of MN-166 (ibudilast) at Annual Meeting of the Society for Neuro-Oncology
Shots:
- The P-II trial evaluates MN-166 (ibudilast) + temozolomide (TMZ) in glioblastoma (GBM) patients (n=62) which included new & recurrent GBM patients. The 1EP of the study was the safety, tolerability & efficacy evaluated by PFS rate at 6mos.
- The result depicted PFS of 44% & 31%, whereas the combination treatment was tolerable & safe. Additionally, immunohistochemistry was examined on pre-treatment tumor tissue to evaluate MIF, pERK, Ki67, CD3, CD11b, & CD74 which showed that patients with progression had higher CD3 tumor infiltration vs those with no progression
- MN-166 (ibudilast) inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, incl. macrophage migration inhibitory factor (MIF)
Ref: MediciNova | Image: MediciNova
Related News:- MediciNova Reports the Completion of Patient Enrollment in the P-II Clinical Trial of MN-166 (ibudilast) for Glioblastoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
